Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Toxicologic pathology: looking ahead.

Bernard A Schwetz1

  • 1US Food and Drug Administration, Rockville, Maryland 20857, USA.

Toxicologic Pathology
|February 25, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessment of phthalates/phthalate alternatives in children's toys and childcare articles: Review of the report including conclusions and recommendation of the Chronic Hazard Advisory Panel of the Consumer Product Safety Commission.

Journal of exposure science & environmental epidemiology·2015
Same author

Protecting subjects without hampering research progress: guidance from the office for human research protections.

Cleveland Clinic journal of medicine·2007
Same author

Workshop proceedings: managing conflict of interest in science. A little consensus and a lot of controversy.

Toxicological sciences : an official journal of the Society of Toxicology·2005
Same author

Toxicological research involving humans: ethical and regulatory considerations.

Toxicological sciences : an official journal of the Society of Toxicology·2005
Same author

Streamlining the clinical research enterprise.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research·2002
Same author

From the Food and Drug Administration.

JAMA·2002
Same journal

New Approach Methodologies (NAMs) for Carcinogenicity Evaluation.

Toxicologic pathology·2026
Same journal

2025 International Academy of Toxicologic Pathology (IATP) Satellite Symposium: Pathology Working Groups (PWGs) in Toxicologic Pathology.

Toxicologic pathology·2026
Same journal

Toxicologic Pathology Forum*: Opportunities and Challenges in the Use of Artificial Intelligence in Nonclinical Toxicologic Histopathology Evaluations.

Toxicologic pathology·2026
Same journal

New Modalities and Carcinogenicity Assessment.

Toxicologic pathology·2026
Same journal

Second Joint Annual Congress of the British Society of Toxicologic Pathology and the European Society of Toxicologic Pathology Special Issue.

Toxicologic pathology·2026
Same journal

Hemangiosarcomas in Intercostal Brown Adipose Tissues of the Sternum Induced by Urethane in TgrasH2 Mice.

Toxicologic pathology·2026
See all related articles

Toxicologic pathology is evolving with new technologies like "-omics" approaches. Adapting to these advancements is crucial for the future role of toxicologic pathologists in product development and regulatory approval.

Area of Science:

  • Toxicologic Pathology
  • Biomedical Science
  • Regulatory Science

Background:

  • The field of toxicologic pathology is undergoing significant transformation.
  • Rapid advancements in science and technology present both opportunities and challenges.
  • The integration of new methodologies is essential for progress.

Purpose of the Study:

  • To highlight the impact of new technologies on toxicologic pathology.
  • To emphasize the need for adaptation and new expertise.
  • To discuss the future role of toxicologic pathologists in product development and approval.

Main Methods:

  • This abstract discusses the transition from traditional toxicology to '-omics' approaches.
  • It emphasizes the need for engagement with new scientific and technological advancements.

Related Experiment Videos

  • The abstract calls for the development of new expertise within the field.

    • Main Results:

    • New technologies offer opportunities to deepen the understanding of toxicology and pathology.
    • These advancements also introduce new challenges that require careful consideration.
    • The successful integration of new approaches is vital for future progress.

    Conclusions:

    • The field must actively engage in the transition towards '-omics' and other new technologies.
    • Developing new expertise is critical to address emerging issues in toxicologic pathology.
    • The adaptability of toxicologic pathologists will shape their future involvement in product development and approval processes.